Media

Horizon BioAdvance Receives Award for Excellence in Clinical Trials
Posted On 07/02/2014

July 2, 2014
 

Lafayette, IN – Horizon BioAdvance announced today that it is one of only eight community oncology practices in the country recognized by the Conquer Cancer Foundation of the American Society of Clin...

We've Moved to a New Location
Posted On 01/13/2014

 January 13, 2014

Horizon BioAdvance's administrative offices have moved to a new location; 3900 McCarty Lane, Suite 107, Lafayette, IN 47905.  The new phone number for this location is 765-250-4477.

Horizon BioAdvance's ...

Horizon Oncology Research, Inc. Participates in Phase II Clinical Study being Presented at ASH
Posted On 12/05/2013

December 5, 2013

Horizon Oncology Research, Inc. participates in the ProNAi Therapeutics Phase II Clinical Trial PNT2258 which will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Lo...

Horizon BioAdvance Supports the Young Investigator Award
Posted On 11/18/2013

Society for Immunotherapy of Cancer

SITC 2013 Annual Meeting, Nov. 8-10, 2013

National Harbor, Maryland- November 9, 2013.  At the 28th Annual Meeting, Horizon BioAdvance proudly supported the Society for Immunotherapy of ...

New Publication in Journal of Translational Oncology
Posted On 11/13/2013

December 2, 2013

News Release:

Horizon Oncology Research, Inc. in Lafayette, Indiana USA collaborates with Fluxion Biosciences Inc. in South San Francisco, CA to prove the efficacy of their novel microfluidic collection workflow ca...

ProNAi to Present Phase II Clinical Data at ASH for PNT2258, a BCL2 Targeted Drug
Posted On 11/13/2013

Plymouth, MI, Nov. 7, 2013 — ProNAi Therapeutics, Inc. a leader in nucleic acid therapeutics, announced that data from its ongoing Phase II clinical study of PNT2258, a novel BCL2 inhibitor, will be presented at the 55th Annual Meeting of th...

News: Horizon BioAdvance Global Expansion
Posted On 10/17/2013

Indiana Biomedical Research Company Expands Internationally

Lafayette, Indiana, USA - April 18, 2013 – Horizon BioAdvance, a leading Indiana biomedical research company, ha...

Blog: What Floats Your Boat?
Posted On 10/17/2013

Recently while promoting the Research Advocacy Program to a local organization with a short presentation, I was asked this question….What floats your boat? What gives you the drive to do what you do? Without hesitation and attempting to hol...

Blog: Clinical Trials: Sowing Seeds of Information and Soothing Patients' Concerns
Posted On 10/17/2013

Many people learn about clinical trials for the first time at the most vulnerable moment of their lives — in their doctor’s office, having just received a cancer diagnosis. No wonder that fewer than five percent of adult cancer patient...

Blog: Skyrocketing Biotech Development Costs & How Horizon Avoids Them
Posted On 10/17/2013

Bringing a drug to market is an extended process with numerous, unpredictable variables. Initial research is just the beginning, as four phases of clinical trials must be completed and regulatory approval given before a drug can be marketed for ge...